| IGM Biosciences is a clinical-stage biotechnology company engaging in the development of Immunoglobulin M (IgM) antibodies for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases. Co.'s product candidates include: IGM-8444, which is an IgM antibody targeting Death Receptor 5 proteins for the treatment of patients with solid and hematologic malignancies; Imvotamab, which is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins; IGM-7354, which is an IgM antibody targeting the delivery of interleukin-15 to the area of PD-L1 expressing cells; and IGM-2644, which is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins. We show 15 historical shares outstanding datapoints in our coverage of IGMS's shares outstanding history.|
Understanding the changing numbers of IGMS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like IGMS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching IGMS by allowing them to research IGMS shares outstanding history
as well as any other stock in our coverage universe.